NCT06827678 Establishment of the Chinese Preclinical Alzheimer's Disease Study With Multiple Neuroimaging
| NCT ID | NCT06827678 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Huashan Hospital |
| Condition | Alzheimer Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,000 participants |
| Start Date | 2022-08-01 |
| Primary Completion | 2027-07-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,000 participants in total. It began in 2022-08-01 with a primary completion date of 2027-07-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to investigate neuroimage and biomarkers in the Alzheimer's continuum in Chinese population. We aimed to: * To reveal the progress of AD by multiple neuroimage and biomarkers; * To reveal the longitudinal change of biomarkers and cognition of AD in Chinese population; * To investigate the interaction of markers between body and brain; * To set up new markers by neuroimage.
Eligibility Criteria
Inclusion Criteria: 1. Cognitive unimpaired(CU) controls: (1) Aged between 45 and 90 years; no gender restrictions； (2) Cognitive function is assessed as normal by the researcher based on cognitive tests, with a Clinical Dementia Rating (CDR) score of 0; (3) Confirmed by the researcher to have no neurological diseases, major chronic illnesses, malignant tumors, or acute infectious diseases; (4) No family history of Alzheimer's disease (AD) or other neurological diseases related to cognitive impairment and movement disorders; (5) Able to understand and provide written informed consent before any assessment; (6) Female subjects must provide medical documentation proving they have undergone surgical sterilization (e.g., hysterectomy, bilateral oophorectomy, or tubal ligation) or have been menopausal for over one year. If they are still of childbearing potential, they must use effective contraceptive measures during the study; (7) Male subjects must use effective contraceptive measures during the study period and are prohibited from donating sperm during this time; (8) Willing and able to comply with all study procedures. 2. Cognitive impaired(CI) patients: 1. Aged between 45 and 90 years; no gender restrictions; 2. CDR score ≥ 0.5; 3. MMSE score ≤ 24; 4. Brain MRI findings support the diagnosis of AD, with no evidence of other neurological diseases; 5. Any medications taken to alleviate AD symptoms must be maintained at a stable dose for at least 30 days before study participation; 6. Written informed consent must be provided by the subject or their legal guardian/caregiver; 7. If necessary, subjects may be accompanied by a caregiver; 8. Before any assessment, the subject or their legal representative must understand and sign a written informed consent form; 9. Female subjects must provide medical documentation confirming surgical sterilization (e.g., hysterectomy, bilateral oophorectomy, or tubal ligation). Exclusion Criteria: * All subjects: 1. Presence of severe neurological diseases or serious disorders affecting the gastrointestinal, cardiovascular, hepatic, renal, hematologic, oncologic, endocrine, respiratory, or immune systems; 2. Presence of MRI-incompatible metal implants, including cardiac pacemakers, intravascular metal devices, insulin pumps, cochlear implants, nerve stimulators, or cerebral aneurysm clips; 3. Inability to tolerate MRI noise or a history of claustrophobia; 4. Exposure to ionizing radiation exceeding 50 mSv within the past year due to participation in other clinical or scientific research; 5. History of drug or alcohol abuse; 6. Pregnancy or lactation; 7. Poor venous access, making repeated venipuncture infeasible; 8. Use of experimental drugs or devices with unknown efficacy or safety within the past month; 9. Allergy to any components of the tracer injection; 10. Any condition that, in the investigator's judgment, may pose a risk or compromise the integrity of the study.
Contact & Investigator
Fang Xie, PhD
PRINCIPAL INVESTIGATOR
Huashan Hospital
Frequently Asked Questions
Who can join the NCT06827678 clinical trial?
This trial is open to participants of all sexes, aged 45 Years or older, up to 90 Years, studying Alzheimer Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06827678 currently recruiting?
Yes, NCT06827678 is actively recruiting participants. Contact the research team at guanyihui@hotmail.com for enrollment information.
Where is the NCT06827678 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT06827678 clinical trial?
NCT06827678 is sponsored by Huashan Hospital. The principal investigator is Fang Xie, PhD at Huashan Hospital. The trial plans to enroll 3,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.